

MARKET REPORT



Multiple Myeloma - Current and Future Players

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Multiple Myeloma - Current and Future Players

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Multiple Myeloma - Current and Future Players

Multiple Myeloma - Current and Future Players

Summary

GlobalData has released its pharma report, "Multiple Myeloma - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Multiple Myeloma Market. The report identifies and analyses the key companies shaping and driving the global Multiple Myeloma market. The report provides insight into the competitive Multiple Myeloma landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

- Investigation of current and future market competition for Multiple Myeloma
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of Multiple Myeloma sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving Multiple Myeloma market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What's the next big thing in the global Multiple Myeloma market landscape? Identify, understand and capitalize

Additional Details

Publisher : Global Data
Reference : GDHC1051FPR
Number of Pages : 83
Report Format : PDF
Publisher Information :

GlobalData»

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for Multiple Myeloma - Current and Future Players [Published by Global Data]

- 1 Table of Contents1 Table of Contents 21.1 List of Tables 41.2 List of Figures 52 Introduction 62.1 Catalyst 62.2 Related Reports 72.3 Upcoming Related Reports 73 Market Outlook 83.1 Global Markets 83.1.1 Forecast 83.1.2 Drivers - Global Issues 153.1.3 Barriers - Global Issues 164 Current and Future Players 184.1 Overview and Trends in Corporate Strategy 184.2 Company Profiles 214.2.1 Millennium Pharmaceuticals/Takeda 214.2.2 Celgene 234.2.3 Onyx Pharmaceuticals/Amgen 254.2.4 Novartis 264.2.5 AbbVie 284.2.6 Bristol-Myers Squibb 294.2.7 Janssen 305 Appendix 325.1 Bibliography 325.2 Abbreviations 545.3 Methodology 585.4 Forecasting Methodology 585.4.1 Diagnosed Multiple Myeloma Patients 585.4.2 Percent of Drug-Treated Patients 595.4.3 Drugs Included in Each Therapeutic Class 595.4.4 Launch and Patent Expiry Dates 605.4.5 General Pricing Assumptions 615.4.6 Individual Drug Assumptions 625.4.7 Pricing of Pipeline Agents 695.4.8 Generic Erosion 765.5 Primary Research - KOLs Interviewed for this Report 775.6 Primary Research - High-Prescriber Survey 795.7 About the Authors 805.7.1 Analyst 805.7.2 Therapy Director 805.7.3 Epidemiologist 805.7.4 Global Head of Healthcare 815.8 About GlobalData 825.9 Disclaimer 82

List Of Tables in Multiple Myeloma - Current and Future Players [Published by Global Data]

1.1 List of Tables

Table 1: Annual Global Sales (\$m) for Multiple Myeloma by Region, 2013-2023 9

Table 2: Annual Global Sales (\$m) for Multiple Myeloma by Drug, 2013-2023 12

Table 3: Global Multiple Multiple Myeloma - Drivers, 2013-2023 15

Table 4: Global Multiple Multiple Myeloma - Barriers, 2013-2023 16

Table 5: Key Companies in the Multiple Myeloma Market Across the 8MM, 2013-2023 19

Table 6: Millennium Pharmaceuticals Multiple Myeloma Therapy Portfolio Assessment, 2015 23

Table 7: Celgene's Multiple Myeloma Therapy Portfolio Assessment, 2015 25

Table 8: Onyx Pharmaceuticals Multiple Myeloma Therapy Portfolio Assessment, 2015 26

Table 9: Novartis' Multiple Myeloma Therapy Portfolio Assessment, 2015 28

Table 10: AbbVie's Multiple Myeloma Therapy Portfolio Assessment, 2015 29

Table 11: BMS' Multiple Myeloma Therapy Portfolio Assessment, 2015 30

Table 12: Janssen's Multiple Myeloma Therapy Portfolio Assessment, 2015 31

Table 13: Multiple Myeloma Diagnosed Incidence, 2013-2023 59

Table 14: Multiple Myeloma Drugs and Pipeline agents, Launch Dates 60

Table 15: Multiple Myeloma Drugs and Pipeline agents, Anticipated Patent Expiries 61

Table 16: Average Cost of Therapy for Velcade 63

Table 17: Average Duration of Treatment (Weeks) for Velcade 63

Table 18: Average Cost of Therapy for Kyprolis (\$) 65

Table 19: Average Duration of Treatment (Weeks) for Kyprolis 65

Table 20: Average Cost of Therapy for Revlimid (\$) 66

Table 21: Average Duration of Treatment (Weeks) for Revlimid 67

Table 22: Average Cost of Therapy for Pomalyst/Imnovid (\$) 68

Table 23 Average Duration of Treatment (Weeks) for Pomalyst/Imnovid 68

Table 24: Average Cost of Therapy for Farydak (\$) 69

Table 25: Duration of Treatment (Weeks) for Farydak 70

Table 26: Average Cost of Therapy for Ixazomib (\$) 71

Table 27: Duration of Treatment (Weeks) for Ixazomib 71

Table 28: Average Cost of Therapy for Empliciti (\$) 72

Table 29: Duration of Treatment (Weeks) for Empliciti 73

Table 30: Average Cost of Therapy for Daratumumab (\$) 74

Table 31: Duration of Treatment (Weeks) for Daratumumab 75

Table 32: Average Cost of Therapy for Daratumumab (\$) 76

Table 33: Duration of Treatment (Weeks) for Daratumumab 76

Table 34: Numbers of Prescribers Surveyed in Each Country 79

List Of Figures, Charts and Diagrams in Multiple Myeloma - Current and Future Players [Published by Global Data]

1.2 List of Figures

Figure 1: Annual Global Sales for Multiple Myeloma by Region, 2013-2023 10

Figure 2: Annual Global Sales for Multiple Myeloma by Region - 2013, 2023 11

Figure 3: Annual Global Sales for Multiple Myeloma by Drug, 2013-2023 13

Figure 4: Global Sales for Multiple Myeloma by Drug, 2013 - 2023 14

Figure 5: Global Sales (\$m) of Branded Products for Multiple Myeloma by Company, 2013 - 2023 20

Figure 6: Company Portfolio Gap Analysis in Multiple Myeloma, 2013-2023 21

How to Buy...

Multiple Myeloma - Current and Future Players [Published by Global Data]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/27220>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$2995** | Single User Price
- \$5990** | Site License Price
- \$8985** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.